Purple Biotech Ltd. has announced promising new data regarding its therapy NT219, a dual inhibitor targeting IRS1/2 and STAT3, for the treatment of head and neck squamous cell carcinoma (HNSCC) and ...

Results from a Phase 1 study of GT-02287 in healthy volunteers demonstrated favorable safety and tolerability, plasma and CNS exposures in the projected therapeutic range, and target engagement with ...

According to MarketsandMarkets™, the Genomic Biomarkers Market is projected to grow from about USD 29.00 billion in 2025 to ...

aiwell Inc., a biotech startup originating from Tokyo University of Science, has identified protein biomarkers associated with menopause. Using its proprietary AI‑driven proteomics platform aiwell IPA ...

The Phase 1b trial consisted of 24 patients with Parkinson’s disease, who received twice-weekly dosing of either HER-096 or placebo over a four-week period. The trial’s exploratory biomarker program ...

Troculeucel, a cryopreserved autologous, non-genetically modified NK cell product, appears to cross the blood brain barrier (BBB) via CXCR3, to reduce neuroinflammation via a simple IV administration.

Aptamer Group plc, the leading developer of next-generation synthetic binders delivering innovation to the life science industry, today announced the launch of its biomarker discovery service, ...

78% reduction in risk of death and 81% reduction in risk of progression or death in defined pretreatment ranges of serum or tumor CEACAM1 subgroup 61% reduction is risk of death and 72% reduction in ...

SynuSight Biotech ("SynuSight"), a biotechnology company dedicated to the development of diagnostic solutions for neurodegenerative diseases and ABLi Therapeutics ("ABLi"), a biotechnology company ...